Rheumatic diseases are painful conditions characterized by inflammation, swelling, and pain in the joints or muscles.
Because of ageing, injuries and traumas, overweight, heritability and excessive stress on the one hand, and a lack of physical activity on the other, joints and related structures such as bones, ligaments and cartilage may develop a series of degenerative disorders that negatively affect daily activities. Among these conditions, the most frequent one is osteoarthritis (OA), which is currently one of the leading causes of disability worldwide. In the EU, OA causes moderate to severe disability in around 40 million people.
OA causes the protective cartilage to wear away and the exposed bones to rub against each other, resulting in a general deterioration of joints, pain and stiffness after periods of inactivity or excessive use.
Knees, hips, hands and spine are the most commonly affected joints.
IBSA products for the treatment of joint diseases:
- IBSA’s leading product for OA treatment is an oral drug containing highly purified, pharmaceutical-grade chondroitin sulfate, effective in treating the pain and functional impairment caused by OA. Additionally, the drug slows the progression of structural changes in joint tissues/cartilage.
- A family of medical devices consisting of a physiological solution of highly purified hyaluronic acid (HA) in a ready-to-use syringe for intra-articular injections, available in different volumes and concentrations. They are indicated for pain or reduced mobility due to degenerative processes, post-traumatic diseases or joint alterations. HA has the capability to increase the viscosity of the synovial fluid. Injections of HA are effectively used in joints suffering from OA (knees, hips, small joints such as the hand) as well as in other pathological conditions of tendons. This family has been further expanded in recent years to include a new member, i.e. a very innovative product containing a solution of hybrid cooperative complexes of hyaluronic acid obtained in a thermal treatment patented by IBSA.